{"timestamp": "2026-01-01 13:36:32", "protocol": "ZEN-301_High_Complexity_Draft", "score": "60.0%", "status": "FAIL", "failures": ["HALLUCINATION: Bolded text not in library: 'Missing Data Handling'", "HALLUCINATION: Bolded text not in library: 'Estimand & Intercurrent Events'", "HALLUCINATION: Bolded text not in library: 'Missing Data Handling'", "HALLUCINATION: Bolded text not in library: 'Estimand & Intercurrent Events'", "HALLUCINATION: Bolded text not in library: 'FDA Historical Precedents'", "HALLUCINATION: Bolded text not in library: 'Missing Data Handling'", "HALLUCINATION: Bolded text not in library: 'Estimand & Intercurrent Events'", "HALLUCINATION: Bolded text not in library: 'Nuisance Parameters & Variance Assumptions'"]}
{"timestamp": "2026-01-01 13:45:00", "protocol": "ZEN-301_High_Complexity_Draft", "score": "60.0%", "status": "FAIL", "failures": ["HALLUCINATION: \"The study had multiple primary endpoints, but the protocol did not describe a method to control the family-wise error rate, which is a requirement for studies with multiple endpoints (21 CFR 314.126).\"", "HALLUCINATION: Missing Data Handling", "HALLUCINATION: \"The use of LOCF for imputing missing data is not acceptable because it can result in biased estimates of treatment effect, particularly in studies with high dropout rates.\"", "HALLUCINATION: Estimand & Intercurrent Events", "HALLUCINATION: Missing Data Handling", "HALLUCINATION: FDA Historical Precedents", "HALLUCINATION: \"The study had multiple primary endpoints, but the protocol did not describe a method to control the family-wise error rate...\"", "HALLUCINATION: Estimand & Intercurrent Events", "HALLUCINATION: Missing Data Handling", "HALLUCINATION: \"The use of LOCF for imputing missing data is not acceptable...\"", "HALLUCINATION: Nuisance Parameters & Variance Assumptions"]}
{"timestamp": "2026-01-01 13:53:43", "protocol": "ZEN-301_High_Complexity_Draft", "score": "60.0%", "status": "FAIL", "failures": ["HALLUCINATION: [FDA Multiplicity Guidance]", "HALLUCINATION: \"procedures to control the Type I error rate should be pre-specified to ensure that the probability of making at least one Type I error does not exceed the desired level of significance\"", "HALLUCINATION: Missing Data Handling", "HALLUCINATION: [ICH E9 (R1)]", "HALLUCINATION: Estimand & Intercurrent Events", "HALLUCINATION: [ICH E9 (R1)]", "HALLUCINATION: Missing Data Handling", "HALLUCINATION: Estimand & Intercurrent Events", "HALLUCINATION: \"An Overview of Multiple Testing Procedures\"", "HALLUCINATION: \"Estimands and Sensitivity Analyses in Clinical Trials\"", "HALLUCINATION: \"Recommendations for the Analysis and Presentation of Outcomes in Clinical Trials in Chronic Pain: Consensus Statement\""]}
{"timestamp": "2026-01-01 13:59:06", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: FWER control is required to maintain the overall Type I error rate at the desired level", "HALLUCINATION: The Estimand Framework: Requires precise definition of 'what' is being estimated", "HALLUCINATION: The choice of method for handling missing data should be pre-specified and should take into account the reasons for the missing data"]}
{"timestamp": "2026-01-01 14:01:01", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: The reviewer notes that the sponsor did not provide a clear justification for the choice of the 0.05 significance level for the secondary endpoints, and the use of a nominal significance level of 0.05 for each secondary endpoint without adjusting for multiplicity is not acceptable.", "HALLUCINATION: The use of LOCF for handling missing data is not acceptable, as it can lead to biased estimates of treatment effects.", "HALLUCINATION: The strategy for handling intercurrent events should be pre-specified and should take into account the specific research question and the characteristics of the intervention.", "HALLUCINATION: The applicant should provide a clear justification for the choice of the significance level and should take into account the multiplicity of tests.", "HALLUCINATION: The use of multiple imputation or MMRM can provide more robust estimates of treatment effects than LOCF.", "HALLUCINATION: The use of a gatekeeping strategy or a Hochberg procedure can provide more robust control of the FWER than the Bonferroni-Holm procedure.", "HALLUCINATION: The reviewer notes that the sponsor did not provide a clear justification for the choice of the 0.05 significance level for the secondary endpoints, and the use of a nominal significance level of 0.05 for each secondary endpoint without adjusting for multiplicity is not acceptable.", "HALLUCINATION: The use of a gatekeeping strategy or a Hochberg procedure can provide more robust control of the FWER than the Bonferroni-Holm procedure.", "HALLUCINATION: The use of LOCF for handling missing data is not acceptable, as it can lead to biased estimates of treatment effects.", "HALLUCINATION: The use of multiple imputation or MMRM can provide more robust estimates of treatment effects than LOCF.", "HALLUCINATION: The strategy for handling intercurrent events should be pre-specified and should take into account the specific research question and the characteristics of the intervention.", "HALLUCINATION: The applicant should provide a clear justification for the choice of the significance level and should take into account the multiplicity of tests.", "HALLUCINATION: The pre-specification of covariates can help to reduce the risk of bias and should be considered in the analysis."]}
{"timestamp": "2026-01-01 18:54:46", "protocol": "ZEN-301_High_Complexity_Draft", "score": "80.0%", "status": "PASS", "failures": []}
{"timestamp": "2026-01-01 19:54:17", "protocol": "Phase 3 Confirmatory Protocol (Full Draft)", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 19:54:18", "protocol": "Oncology Phase 3: Structural Integrity Test", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 19:54:18", "protocol": "Diabetes Type 2: Legacy Methodology Trap", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 19:54:19", "protocol": "Alzheimer's Phase 3: The Multiplicity Kitchen Sink", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01", "score": "0.0%", "status": "FAIL", "protocol": "Phase 3 Confirmatory: Legacy LOCF Trap"}
{"timestamp": "2026-01-01", "score": "0.0%", "status": "FAIL", "protocol": "Oncology: Multiplicity Alpha Inflation"}
{"timestamp": "2026-01-01", "score": "0.0%", "status": "FAIL", "protocol": "Dynamic_Multiplicity Alpha Inflation"}
{"timestamp": "2026-01-01", "score": "0.0%", "status": "FAIL", "protocol": "Dynamic_Legacy LOCF Bias"}
{"timestamp": "2026-01-01 19:57:58", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 19:59:43", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01", "score": "0.0%", "status": "FAIL", "protocol": "Phase 3 Confirmatory: Legacy LOCF Trap"}
{"timestamp": "2026-01-01", "score": "0.0%", "status": "FAIL", "protocol": "Oncology: Multiplicity Alpha Inflation"}
{"timestamp": "2026-01-01 20:02:56", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 20:04:04", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 20:07:51", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 20:09:15", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 20:09:51", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 20:12:25", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 20:42:37", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 21:23:00", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 21:25:43", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 21:26:08", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 21:28:38", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: We have concluded that your application does not provide sufficient data for the Division to approve your application for the proposed indication of treatment of negative symptoms of schizophrenia because of the following deficiencies briefly outlined below:", "HALLUCINATION: The primary efficacy analysis during the randomized withdrawal period was to be based on the Efficacy Analysis Set, a subset of the intent-to-treat (ITT) population, which was intended to enrich for a responder population.", "HALLUCINATION: We have concluded that your application does not provide sufficient data for the Division to approve your application for the proposed indication of treatment of negative symptoms of schizophrenia because of the following deficiencies briefly outlined below:", "HALLUCINATION: The primary efficacy analysis during the randomized withdrawal period was to be based on the Efficacy Analysis Set, a subset of the intent-to-treat (ITT) population, which was intended to enrich for a responder population."]}
{"timestamp": "2026-01-01 21:35:04", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: missing values at Week 24 will be handled via the Last Observation Carried Forward (LOCF) method"]}
{"timestamp": "2026-01-01 21:40:01", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: FDA Multiplicity Guidance (2022) Section III"]}
{"timestamp": "2026-01-01 21:43:40", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: We have concluded that your application does not provide sufficient data for the Division to approve your application for the proposed indication of treatment of negative symptoms of schizophrenia because of the following deficiencies briefly outlined below: (1) You have not established substantial evidence of effectiveness (SEE) for the effects of roluperidone on the negative symptoms of schizophrenia.", "HALLUCINATION: In both monotherapy trials, tenapanor\u2019s efficacy in reducing serum phosphorus levels was assessed in a randomized, double-blind, placebo-controlled withdrawal period."]}
{"timestamp": "2026-01-01 21:58:34", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: Although we agree that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis, the magnitude of the treatment effect is small and of unclear clinical significance."]}
{"timestamp": "2026-01-01 22:01:05", "protocol": "ZEN-301_High_Complexity_Draft", "score": "80.0%", "status": "PASS", "failures": []}
{"timestamp": "2026-01-01 22:03:00", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 22:03:31", "protocol": "ZEN-301_High_Complexity_Draft", "score": "40.0%", "status": "FAIL", "failures": ["HALLUCINATION: The primary objective of this study is to evaluate the clinical efficacy of Zenziva 20mg once daily compared to placebo in reducing depressive symptoms."]}
{"timestamp": "2026-01-01 22:09:13", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
{"timestamp": "2026-01-01 22:12:32", "protocol": "ZEN-301_High_Complexity_Draft", "score": "0.0%", "status": "FAIL", "failures": []}
